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Abstract
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This study tested the hypothesis that B cells from salivary tissue are distinct in terms of proliferative
capacity, immunoglobulin M secretion, repertoire, and autoantibody enrichment in Sjögren’s syndrome.
We sorted purified B cells from the spleen, cervical lymph nodes, and submandibular glands of a primary
Sjögren’s syndrome mouse model (Id3−/−). Enzyme-linked immunospot and proliferation assays were
performed with stimulated B cells. We single-cell sorted B cells from the spleen, cervical lymph nodes,
and submandibular gland tissue from Sjögren’s syndrome mice and sequenced immunoglobulin M heavychain variable regions. Finally, autoantigen arrays were performed using immunoglobulin M derived from
sera, cervical lymph nodes, spleens, and submandibular gland tissue of Id3−/− animals. Results suggest B
cells from salivary tissue of Sjögren’s syndrome mice are similar to those from secondary immune sites in
terms of proliferative and secretory capacity. However, differences in repertoire usage, heavy chain
complementarity-determining region 3 length, mutational frequency, and N region addition were observed
among B cells derived from submandibular gland, cervical lymph node, and spleen tissue. Moreover,
autoantigen array data show immunoglobulin M from salivary B cells have enriched specificity for Ro
(Sjögren’s syndrome A) and La (Sjögren’s syndrome B). All together, these data suggest salivary B cells
have unique repertoire characteristics that likely influence autoantigen binding and contribute to Sjögren’s
syndrome disease in a tissue-specific manner.
Keywords: salivary gland, sialadenitis, B cell repertoire, Id3−/−

Introduction
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SS is an autoimmune disease that primarily affects women. The disease occurs in 2 forms, termed pSS and
secondary SS. In pSS, the disease targets exocrine tissue, resulting in debilitating loss of glandular
secretions. In addition, many other serious systemic disease manifestations are observed [1]. In secondary
SS, another autoimmune connective tissue disease is present as well, most commonly systemic lupus
erythematosus or rheumatoid arthritis [2].
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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One of the hallmarks of SS is inflammation of the salivary tissue, termed focal lymphocytic sialadenitis
[3]. The lymphocytic infiltrate in SS comprises both B and T cells, and the percentage of B cells in
diseased salivary tissue increases over time [4]. B cell dysfunction is well established in SS, and there are
several lines of evidence that implicate B cells in SS development. Notably, numerous autoantibodies are
seen in patients with SS [5], and a recent study [6] shows these may be present even before the onset of
symptoms. Detection of anti-Ro (anti-Sjögren’s syndrome A) and anti-La (anti-Sjögren’s syndrome B)
antibodies aid in diagnosis [7], and antibodies directed against nuclear antigens and RF are included in the
SS diagnostic algorithm [8].
For this study, we chose to examine the B cell repertoire in the pSS model Id3−/− [9]. We used Id3−/−
animals because they develop SS in the absence of other autoimmune diseases; therefore, they represent a
good model to study systemic immune changes resulting from SS specifically. Although the phenotypic
properties of B cells from Id3−/− animals have not been studied extensively, work by Pan et al. [10]
demonstrates normal percentages of B cells in lymphoid tissues, although a more recent study [11] shows a
decrease in the fraction of splenic marginal zone B cells in this model. Importantly, these animals show
equivalent levels of serum IgM, IgG2b, IgG3, and IgA when compared with C57BL/6 wild-type controls,
and Id3−/− B cells proliferate normally in response to LPS, anti-IgM + IL-4, and CD40 ligand [10].
However, B cells from Id3-deficient animals show reduced serum IgG1 and IgG2a titers, and B cell
proliferation is decreased following BCR cross-linking with F(ab′)2 fragments. In addition, Id3−/− B cells
demonstrate diminished responsiveness to T dependent and T independent antigens following
immunization [10]. Despite these differences, B cells derived from Id3−/− animals facilitate the study of
humoral immunity in pSS because they reliably produce anti-Ro and anti-La autoantibodies [9] and have
IgM levels within reference range. In addition, salivary gland infiltrates in this model are composed of
both B and T cells, allowing for analyses of B cells in salivary tissue in the context of disease [9].
Although many studies show B cells contribute to SS pathology, it is not clear where these autoreactive B
cells reside and whether B cells within salivary tissue have distinct functional properties as compared with
B cells derived from secondary immune sites. Accordingly, it is not known whether pathogenic B cells
enter the salivary tissue in a stochastic manner or whether defects in B cell development or selection give
rise to a population of cells with certain repertoire characteristics that target salivary gland tissue
preferentially. Because the B cell compartment expressing IgM is clearly dysregulated in human SS [12],
we chose to focus on these cells.
Several studies show an important role for IgM+ B cells in SS disease pathogenesis. Specifically, patients
with pSS show significantly more mutated CD27+ memory Cμ transcripts as compared with corresponding
Cγ or Cα transcripts [13]. In addition, patients with SS have a high risk of developing non-Hodgkin
lymphomas [14]. Such malignancies frequently show clonal expansion of B cells expressing IgM [15, 16],
and 2 studies of patients with SS and lymphoma demonstrate clonal IgM+ RF B cells [17, 18]. Importantly,
results from the Sjogren’s International Collaborative Clinical Alliance study [8] suggest serologic RF
positivity should be included as part of the new diagnostic criteria for SS. These findings indicate that
development of lymphomas may be driven by chronic autoantigen engagement of IgM-expressing B cells
[19]. Therefore, several lines of evidence point to disturbed IgM+ B cells in SS that are associated with
autoimmunity and malignancy. Thus, it is important to identify the underlying reasons for IgM
abnormalities in patients with SS and also to understand the triggers for autoantibody production in this
population to prevent lymphoma development and mitigate B cell–driven pathology in SS.
This study used a pSS murine model to determine whether B cells within salivary tissues have unique
characteristics that may be amenable to therapeutic manipulation. We performed extensive analyses on the
IgM heavy-chain variable region of sequences from the SMG, cLN, and spleen in a pSS model, and we
used an autoantigen array to examine differences in autoantibody binding specificities among IgM derived
from sera, SMG, spleen, and cLNs in these animals. Importantly, IgM derived from salivary B cells
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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exhibits unique repertoire features and is enriched for anti-Ro and anti-La reactivity, suggesting
distinguishing characteristics inherent in IgM derived from B cells in salivary tissue. Such findings have
important implications for understanding SS pathogenesis and will aid in the design of therapeutics that
target B cells in SS.

MATERIALS AND METHODS

Go to:

Mice
B6.129S-Id3tm1Zhu/J (Id3−/−) and C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). Id3−/− animals were backcrossed to the C57BL/6 strain for 11 generations
(http://jaxmice.jax.org/strain/006301.html). Both male and female C57BL/6 and Id3−/− animals were used
because this strain demonstrates SS disease with equal sex predilection. All C57BL/6 and Id3−/− animals
were >6 months old at the time of death, consistent with the time of disease development [9]. Animals
were killed using CO2. Mice were cared for and handled in accordance with Institutional Animal Care and
Use Committee and U.S. National Institutes of Health guidelines.
Cell isolation, flow cytometry, and sorting
B cells were isolated from spleens, cLNs, and SMG tissue of pSS (Id3−/−) mice. Appropriate age- and sexmatched controls were used. Splenocytes and cLN cells were isolated by mechanical disruption. SMG
tissue was isolated as previously described [20]. Splenocytes were stained by immunofluorescence for
B220 (BD Biosciences, Franklin Lakes, NJ, USA), CD23 (Abcam, Cambridge, MA, USA), CD21/35 (BD
Biosciences), and AA4.1 (BioLegend, San Diego, CA, USA) or IgM (BioLegend). Fo B cells (B220+,
CD23+, CD21/35int) from splenic tissue were sorted and purified using Influx or FACS Aria instruments
(BD Biosciences). cLN B cells (B220+, CD23+, CD21/35int) were sort-purified similarly. B cells from
SMG tissue were stained fluorescently with F4/80 (eBioscience, San Diego, CA, USA), B220, and CD4
(BD Biosciences). B cells (B220+, CD4-, F4/80-) from SMG samples were sort-purified as described for
spleen and cLN samples. All incubations were performed on ice. Briefly, cells were incubated with
CD16/32 (BD Biosciences) in staining buffer (2% FBS in PBS) for 30 min, followed by addition of
fluorescently labeled antibodies at a 1:1000 dilution for 30 min. Cells were washed once in staining buffer,
and sorted at a concentration of 1 × 107/ml. Gating strategies are shown in Supplemental Fig. 1.
IgM secretion
IgM secretion was measured by ELISPOT assay, as previously described [21]. B cells were isolated from
spleen, cLN, and SMG tissue of SS mice and sort-purified, as described above. Splenic and cLN samples
from individual mice were evaluated, whereas SMG samples were pooled because of the limited number
of B cells recovered per gland. B cells from spleen and cLNs of age- and sex-matched control mice were
also harvested. Cells were cultured in RPMI 1640 medium containing 5% heat-inactivated FBS, 2 mM glutamine, 50 μM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin in duplicate in 96well U-bottom plates. B cells were stimulated with LPS (25 μg/ml) for 72 h before assay. B cells were
counted with an automated cell counter (ADAM, Bulldog Bio, Portsmouth, NH, USA) and were plated
onto MultiScreen-IP Plates (Millipore, Billerica, MA, USA) (2000 cells/well). Plates were precoated with
goat anti-mouse Ig (H + L) (Southern Biotech, Birmingham, AL, USA) and then incubated for 3 h at 37°C
and 5% CO2. Plates were treated with alkaline phosphatase–conjugated goat anti-mouse IgM (Southern
Biotech) and developed with 5-bromo-4-chloro-3-indolyl phosphate/p-NBT chloride substrate (KPL,
Gaithersburg, MD, USA). Each sample was plated in duplicate. The total number of ELISPOTs for each
sample and mean spot-size calculations were carried out using ImmunoSpot (CTL, Shaker Heights, OH,
US) or KS ELISPOT software and an Axiocam MRc camera (Zeiss, Pleasanton, CA, USA).
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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Proliferation
B cells were isolated from spleen, cLN, and pooled SMG tissue of SS and control mice, as described
above. Proliferation was measured by thymidine incorporation, as previously described [22]. Cells (2.5 ×
104/well) were cultured as described above and stimulated for 72 h with LPS (25 μg/ml). Cultures were
pulsed with 0.5 μCi of [3H]thymidine (Amersham, Pittsburgh, PA, USA) or BrdU for 6 h before the end of
the 72-h culture. Thymidine incorporation was measured by scintillation counting of β-particle emissions
(Beckman Coulter, Brea, CA, USA). BrdU incorporation was measured using a BrdU cell proliferation kit
(EMD Millipore, Billerica, MA, USA).
Single cell sorting, PCR, and sequences
Splenic and cLN Fo B cells (B220+, CD23+, CD21/35int, IgM+) and B cells from SMG tissue (B220+,
CD4−, F4/80−) were fluorescently stained and were single-cell sorted onto AmpliGrid slides (Beckman
Coulter) or 96 well plates (Denville, South Plainfield, NJ, USA) using an Influx sorter or FACSAria,
respectively (BD Biosciences). OneStep reverse transcription and PCR (Qiagen, Valencia, CA, USA) were
carried out with 2 primers [23], each at 0.6 μM (MsVH E =
GGGAATTCGAGGTGCAGCTGCAGGAGTCTGG; MsCμ E = ATGGCCACCGAATTC TTATCAGA),
as follows: 49°C for 30 min; 94°C for 15 min; 35 cycles at 93°C for 30 s, 49°C for 30 s, 71°C for 30 s; and
then a final extension at 71°C for 10 min (AmpliSpeed PCR cycler, Advalytix or C1000, BioRad,
Hercules, CA, USA). Contents of the reaction were then removed from the center of each well and diluted
with distilled H2O. A second, seminested amplification was then performed using the same MsVH E
primer and an internal, constant-region primer (MsCμ N =
TGTAAAACGACGGCCAGTCATTTGGGAAGGACTGA) plus the first-round PCR product. The PCR
reaction was as follows: 95°C for 15 min, 40 cycles at 94°C for 30 s, 50°C for 30 s, 72°C for 30 s, and a
final extension at 72°C for 10 min. Sequencing was performed by Biotic Solutions (TACGen, San Pablo,
CA, USA) or Genewhiz (South Plainfield, NJ, USA).
Repertoire analyses
The International ImMunoGenecTics Information System (IMGT, Montpellier Cedex, France) was used to
determine IgM heavy chain (H) usage of variable (V), diversity (D), and joining (J) regions [24, 25].
Analysis of the CDR-H3 sequence, length, mutational frequency, and N region addition was also
performed using IMGT. The hydrophobicity and the charge of the CDR-H3 regions were determined using
HeliQuest (http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParamsV2.py). In-frame sequences were used for
analysis.
Autoantigen arrays
B cells were sort-purified from spleen, cLN, and SMG tissue of Id3−/− mice as described above. Cells (1 ×
105/well) were cultured in 5% RPMI 1640 medium, stimulated with LPS (25 μg/ml) for 6 d, and
supernatants were harvested. These undiluted supernatant samples and sera were used for protein array
analysis at the Microarray Core Facility of the University of Texas Southwestern Medical Center (UTSW;
Dallas, Texas, USA). Autoantigen arrays bearing 90 autoantigens and 8 control proteins (human IgG,
human IgM, mouse IgG, mouse IgM, anti-human IgG, anti-human IgM, anti-mouse IgG, and anti-mouse
IgM) were printed in duplicate on nitrocellulose film–coated ONCYTE SuperNOVA 16 slides (Grace BioLabs, Bend, OR, USA). The samples were incubated with the autoantigen arrays, and autoantibodies were
detected with cy5-labeled anti-mouse IgM using a Genepix 4200A scanner (Molecular Devices,
Sunnyvale, CA, USA) with laser wavelengths of 532 nm and 635 nm. The resulting images were analyzed
using Genepix Pro 6.0 software (Molecular Devices). The median signal intensity for each spot was
calculated and subtracted from the local background around the spot, and data obtained from duplicate
spots were averaged. Internally spotted IgG and IgM were used as controls for normalization across the
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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arrays. The anti-IgG and anti-IgM antibodies were used for measuring the total IgG and IgM bound to the
anti-IgG and anti-IgM antibodies on the arrays. Finally, the net fluorescence intensity for each antigen was
calculated by subtracting a PBS control that was included for each experiment as the negative control. The
signal-to-noise ratio was used as a quantitative measurement of the ability to resolve the true signal from
background noise. Signal-to-noise ratio values ≥3 were considered significantly greater than background
and, therefore, were true signals [26, 27]. The autoantigens and controls on the autoantigen array are listed
on the UTSW Microarray Core Facility core website:
(http://microarray.swmed.edu/products/product/autoantigen-microarray-panel-i/). The purified
autoantigens were ordered from different commercial sources, including Sigma Aldrich (St. Louis, MO,
USA), Life Technologies (Waltham, MA, USA), BD Biosciences, SurModics (Eden Prairie, MN, USA),
Meridian Bioscience (Cincinnati, OH, USA), R&D Systems (Minneapolis, MN, USA), and Abcam. The
validation of the autoantigen microarrays is described in several previous publications [26–33]. Individual
autoantigen array assay values for IgM are shown in Supplemental Table 1. The background-subtracted,
median signal intensity of each antigen was normalized by the Microarray Core Facility using standard
practices, (i.e., with the appropriate internal controls for each data set and the average intensity of total
mouse IgM). The heat map figures and statistical tests were generated and performed by D.P.G. using R
software (https://www.r-project.org/). The autoantigen array accession number is GSE62176. The data can
be accessed at http://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/geo/query/acc.cgi?acc=GSE62176.
Statistical analysis
Mann-Whitney and χ2 tests were done using Prism (GraphPad Software Inc., La Jolla, CA, USA).
Analysis of the array data revealed a batch effect (i.e., 2 sets of samples were run more than a year apart on
different versions of the array) that could not be easily corrected by a linear or simple nonlinear
transformation. Hence, analysis of the array data was conducted stratified according to the 2 “runs.”
Expression of Ro-52, Ro-60, and La signals were hypothesized to be greatest in SMG samples. Simple
rank-sum tests were performed to test this hypothesis. The ranks (across samples for each run) of each of 3
autoantigens were computed for the SMG sample (for each run). The total rank-sum values were then
compared with the rank-sum values from all samples (within run), whereby the samples were permuted
with respect to their assay values.

RESULTS

Go to:

B cells from salivary tissue, spleen, and cLNs secrete similar levels of IgM
To determine whether B cells from salivary tissue secrete enhanced levels of Ig as compared with B cells
isolated from other immune sites, we stimulated sort-purified Id3−/− B cells from cLNs, spleen, and SMG
salivary tissue with LPS and performed ELISPOT assays. We found no differences in the percentage of B
cells secreting IgM from SMG, spleen, and cLNs in the Id3−/− and control C57BL/6 animals (Fig. 1A).
Healthy animals do not have lymphocytes within salivary tissue, so we could not compare SMG
lymphocytes from healthy control animals with those with SS. There were no differences when we
compared the percentage of IgM secretion-positive salivary B cells with those from cLN and spleen,
suggesting that B cells in salivary tissue in SS are similar in the percentage of cells that produce antibodies
as compared with those from secondary immune sites.
To determine whether antibody secretion per cell is enhanced in the SMG population, we examined the
mean spot size for each sample. Analysis of Id3−/− and C57BL/6 B cells isolated from the spleen, cLN,
and SMG revealed no differences in the amount of IgM secreted (Fig. 1B). Together, these findings
suggest salivary B cells are similar to those from other immune sites in the percentage of cells that secrete
IgM and also in the amount of antibody secreted per B cell in pSS.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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B cells from salivary tissue are not as hyperproliferative in response to LPS as compared
to those from other immune sites
To test whether salivary gland B cells are hyperproliferative, we stimulated B cells from Id3−/− animals
and measured proliferation (Fig. 2). B cells derived from splenic tissue showed greater proliferation
following LPS stimulation than did splenic B cells from C57BL/6 animals (P < 0.0001) and Id3−/− cLNs
(P = 0.01). Interestingly, Id3−/− B cells derived from salivary tissue proliferated similar to B cells derived
from cLNs (P = 0.6) but showed reduced proliferation when compared with those from the spleen (P =
0.04). B cell proliferation was similar in cLN B cells derived from Id3−/− and C57BL/6 control animals (P
= 0.2). Thus, results from our proliferation studies show salivary gland B cells do not display a
hyperproliferative phenotype in response to LPS stimulation and, thus, are not distinguishable from B cells
isolated from other sites based on Tlr4-mediated proliferation.
The IgM heavy-chain repertoire differs in B cells derived from SMG tissue, cLNs, and
spleen
To determine whether B cells in salivary tissue have unique repertoire characteristics, we single-cell sorted
B cells from Id3−/− SMG, cLN, and spleen. Splenic and cLN B cell sequences were generated from 4
independent experiments, each with spleens pooled from 4 – 5 animals. SMG B cell sequences were also
generated from 4 independent experiments, with SMG tissue from 8–10 animals pooled for each
experiment. We performed sequence analysis on IgM from Id3−/− B cells derived from spleen (n = 265),
cLN (n = 59), and SMG tissue (n = 63). VH usage was similar among B cells isolated from the 3 sites,
with the exception of skewed VH14 usage by Id3−/− splenocytes and cLNs (P = 0.02 and P = 0.01,
respectively) (Fig. 3A). Differences were also seen in DH usage. Interestingly, IgM derived from Id3−/−
SMG B cells and cLN cells had increased DH4 use as compared with spleen (P = 0.006 and P = 0.01,
respectively) (Fig. 3C). JH usage was also skewed because IgM from Id3−/− spleen showed more frequent
usage of JH4 than that from salivary tissue (P = 0.03) Moreover, salivary IgM showed increased JH1
usage as compared with cLN (P = 0.05) (Fig. 3B). Of note, the CDR-H3 length of IgM derived from Id3−/
−
SMG B cells was shorter than that of spleen (average lengths = 11.6 vs. 12.4 amino acids, respectively (P
= 0.02) (Fig. 4A). However, CDR-H3 hydrophobicity and charge were similar in each of the sites we
examined (Fig. 4B and C, respectively).
In addition, we evaluated the mutational frequency of the heavy chain variable region from Id3−/− B cells (
Fig. 5A). Surprisingly, there were no significant differences seen among salivary, cLN, and splenic IgM.
Finally, we examined N region additions. Interestingly, B cells derived from salivary tissue showed
significant differences because IgM from SMG B cells was enriched for sequences that lacked N region
additions as compared with spleen (P = 0.007). Moreover, salivary B cells had more N region additions at
the V–D junction (P = 0.0002 and P = 0.0005) and also fewer sequences that contained N additions at both
junctions as compared with spleen and cLN (P < 0.0001 and P = 0.0003, respectively) (Fig. 5B). Finally,
we compared CDR-H3 amino acid usage between IgM derived from SMG, cLN, and spleen (Fig. 6). We
found that amino acid usage was similar among all populations, although methionine was used more often
in the splenic IgM than it was in the salivary IgM (P = 0.01). Taken together, these data suggest that
significant differences exist in VH, DH, and JH usage, as well as CDR-H3 length and N region addition of
salivary gland–derived IgM that may alter or enhance self-antigen recognition in this population.
SS autoantibodies are enriched in IgM derived from salivary gland B cells in Id3−/− mice
Although Ig sequencing studies reveal fundamental differences in the repertoire, they do not allow for
predictions regarding antigen specificity. To investigate cognate antibody interactions, we collected sera
and sort-purified B cells from spleen, cLNs, and SMG tissue from Id3−/− animals. We cultured those cells
with LPS as described in “Materials and Methods” and collected the supernatants. We then performed
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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autoantigen arrays to detect IgM reactivity to the SS autoantigens Ro and La. Antibodies to La and both
Ro isoforms (Ro60 and Ro52) are screened for as part of the diagnostic algorithm for SS [34].
Significantly, IgM derived from salivary B cells showed enriched reactivity for Ro60, Ro52, and La/SSB
autoantigens, whereas a diminished signal was present when IgM from other sites and control animals was
incubated with these autoantigens (Fig. 7). Taken together, these data demonstrate that reactivity to the SS
autoantigens Ro and La lies preferentially in IgM derived from salivary gland B cells.

DISCUSSION
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We used a well-established pSS model (Id3−/−) to explore differences in IgM+ B cell function and
repertoire between secondary immune sites and salivary tissue. Importantly, this model has many
similarities to human SS because Id3−/− mice exhibit spontaneous disease development, lymphocytic
infiltration of salivary tissue, and loss of salivary flow. In addition, Id3−/− mice have autoantibodies to Ro
and La [9, 35]. Results from this study show salivary B cells share similar functional characteristics with B
cells from other immune sites in pSS. However, we observed skewing of VH, DH, and JH gene usage,
shorter CDR-H3 lengths, fewer N region additions in salivary gland B cells, and enriched anti-Ro and antiLa binding specificity in IgM produced by salivary gland B cells. In summary, these data show there are
significant differences between IgM antibodies in salivary tissue and those from other immune sites, and
this suggests tissue specificity of the immune response that may arise during development or as a result of
antigen-driven selection or both. These findings strengthen our current understanding of IgM dysregulation
in SS pathogenesis.
B cells are emerging as important therapeutic targets in several types of autoimmunity because they
promote disease through interactions with T cells, secrete proinflammatory cytokines and autoantibodies,
and migrate to diseased tissue where they may drive or exacerbate inflammation.
B cells are clearly dysregulated in SS disease. Although the presence of antibodies directed against Ro and
La are included in the current diagnostic criteria [7], many reports have documented numerous
autoantibodies in SS [5]. Although many of the autoantibodies identified in SS are common to other
autoimmune connective tissue diseases, such as antinuclear antibodies and RF [36, 37], some are unique
and are reported to have functional consequences [38]. For example, anti-M3 muscarinic acetylcholine
receptor M3 autoantibodies are identified in patients with SS and these diminish salivary flow in human
salivary gland cells [39]. Notably, a complementary study using a mouse model of SS that was deficient in
autoantibody production maintained normal salivary flow, suggesting a pathogenic role for B cells in SSinduced xerostomia [40]. Thus, autoantibodies are clearly hallmarks of disease and are likely directly
involved in disease progression and symptomology.
Surprisingly, we did not observe a hyperproliferative phenotype in salivary B cells in response to LPS
stimulation. However, it is possible that Tlr4 expression differs between salivary B cells and those from
secondary immune sites, and further studies are needed to determine whether Id3−/− salivary B cells are
hyporesponsive to LPS. Of note, our results differ from a previously published study that examined LPSinduced proliferation of splenic B cells in Id3−/− animals [10]. Variances between the experimental
approaches may account for the incongruous results. In the previous study, proliferation assays were
performed using mice derived from the 129/SV–C57BL/6 mixed background, whereas our mice were
derived from the C57BL/6 strain [10]. It is also important to note differences in B cell isolation. In the
previous study, total splenic B cells (including several subpopulations, such as marginal zone, germinal
center, and B-1 in addition to Fo) were purified by negative selection, whereas we isolated Fo B cells using
positive selection [10]. Thus, differences in genetic background and population heterogeneity could
contribute to the disparate results.
Several studies have examined the B cell antibody repertoire in both health and disease. Such studies have
focused on the CDR3 region because sequence diversity in this region is particularly important for antigen
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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recognition [41]. In-depth analysis of the CDR-H3 region in murine splenic B cells shows that the average
length, charge, and hydrophobicity are tightly controlled during development [42], and there is a loss of
charged and hydrophobic CDR-H3s in the mature B cell repertoire in healthy animals [43]. Results from
our study show that B cells derived from salivary tissue do not show any differences in CDR-H3
hydrophobicity or charge. However, shorter CDR-H3 lengths were observed in IgM derived from salivary
tissue as compared with those from spleen. This is consistent with our N region addition data because IgM
from salivary B cells showed fewer N region additions as compared with spleen and cLN, and the number
of N region additions is known to influence CDR3 length [23]. We found amino acid usage in the CDR-H3
region was similar among salivary, cLN, and splenic B cells, although methionine was used more
commonly by the splenic B cells as compared with those from salivary tissue. Although the significance of
this is not known, a study comparing the CDR-H3 regions from Ig derived from bone marrow from TdTdeficient mice to wild type found that the TdT−/− adult bone marrow Ig (which parallels fetal liver in
lacking TdT) was virtually devoid of several amino acid residues, including methionine [44]. The paucity
of N region addition, increased usage of DH4, and the decreased use of methionine suggest that the IgM
repertoire of salivary B cells is reminiscent of early B fetal cells. This finding is surprising because the
germline repertoire is generally thought to confer protection from autoimmunity [45]. Thus, it is possible
that these “natural” IgM antibodies in salivary tissue are produced as part of a compensatory protective
mechanism [46].
Natural antibodies are produced primarily by marginal zone and B-1 cells [46–48]. Although several
studies have examined B cell subsets in SS [13, 49, 50], it remains unclear as to which subset or subsets
provide the most significant source of autoantibodies in this disease. Although we focused on follicular B
cells in this report, it is also possible that marginal zone or B-1 cells contribute to IgM autoantibody
production in SS and may be present within salivary tissue. Studies using BAFF transgenic animals show
evidence of a lupus-like disease and SS. These animals have an expanded marginal-zone compartments,
and marginal zone and B-1 cells are identified in salivary tissue, suggesting these subsets may have a role
in SS [51]. However, Id3−/− animals have reduced marginal-zone B cells and also develop disease, so the
role of the marginal-zone subset in SS is unclear at present [11]. In addition, B-1 cells are implicated in
autoimmune disease in mice and humans [52–54], although evidence for this subset in autoimmunity is
limited. Thus, further studies are needed to determine whether the autoreactive IgM detected in salivary
tissue is derived, at least in part, from B-1 or marginal-zone B cells in SS disease.
Although the significance of the shorter CDR-H3s in salivary tissue is not clear, alterations in this region
are likely to modify antibody specificity in a pathogenic manner [41]. Accordingly, short IgM CDR-H3
regions are seen in both murine and human lupus [55, 56], and antibodies isolated from parotid tissue of a
patient with SS showed shorter CDR-H3 regions as compared with peripheral blood [57]. Although studies
suggest short CDR-H3 regions may be indicative of autoreactivity, there is evidence that longer CDR3
regions may also correlate with polyreactivity or autoreactivity [58–60]. Because CDR3 length is tightly
controlled during development [42, 43], any deviation from this constraint may be indicative of pathology.
Importantly, there are no CDR-H3 sequence characteristics that are known to confer reactivity for Ro or
La, so it is not clear whether these differences influence binding of these autoantigens specifically.
The B cell repertoire in SS models and patients has not been studied extensively, likely because of the
inherent difficulty in isolating B cells from salivary gland tissue in sufficient amounts for these types of
analyses. Moreover, it is difficult to acquire tissue from secondary immune sites of patients with SS. To
our knowledge, no studies to date have compared repertoire specificity of IgM derived from SMG to
secondary immune sites, although, one recent study [61] used a pSS model to show greater IgG1 isotype
specificity against salivary gland lysates from antibody derived from salivary tissue as compared with that
from cLNs. Limited studies in patients with SS have compared the salivary gland B cell heavy-chain
repertoire to other sites. Results of these studies demonstrated most Ig isolated from lymph nodes and
salivary tissue of 2 patients with pSS is polyclonal in nature [62]. Importantly, significant differences were
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seen in the proportion of cells expressing mutated VH rearrangements, and those in salivary tissue were
increased as compared with those in peripheral blood [57, 62].
Although the numbers of patients analyzed in these aforementioned studies is small, together these data
suggest that patients with SS have a polyclonal B cell repertoire, and repertoire differences may exist
between salivary gland and peripheral B cells in humans [63]. Results from our study herein are consistent
with the limited human repertoire analyses available to date. Although we did not see differences in
somatic hypermutation between IgM derived from the spleen and salivary tissue, we found the vast
number of sequences from our pSS model were polyclonal (data not shown), and our results show IgM
derived from salivary B cells has relatively short CDR-H3 regions. At present, it is not clear why the
mutational frequency we observed in salivary tissue in mice differs from that reported in humans. This
may be due to differences between murine and human SS. Alternatively, our repertoire analyses focused
solely on IgM, whereas human studies examined all Ig isotypes in the tissue. Thus, it is possible that the
difference in our results may reflect the variance in mutational frequencies between IgG and IgM classes in
SS.
The significance of the repertoire differences observed between IgM derived from salivary and splenic B
cells is poorly understood at present. However, there are discrete changes that affect small numbers of B
cells that may, in fact, be the pathogenic B cells in our model. It is clear that even slight repertoire skewing
can have a dramatic effect on the biologic function of a particular B cell subset. For example, the B-1a cell
repertoire is skewed toward VH11 and VH12 [64–66]. Although only 5–10% of the population exhibits
this VH usage, this results in preferential recognition of phosphatidylcholine by B-1a cells [67]. Studies
show that this phosphatidylcholine specificity has an important protective role in a model of sepsis [68].
Thus, B-1a cells provide a notable example of the importance of repertoire skewing in innate defense, and
this has biologic significance, even though the actual percentage of VH11/12-expressing cells in the
population is low. Therefore, it may well be that the skewed repertoire observed in salivary-derived IgM
confers self-reactivity and is significant in SS disease pathogenesis, and further studies are needed to
determine how such molecular differences may be directly related to the increased reactivity to
autoantigens Ro and La observed in the salivary-derived IgM.
Strikingly, we show for the first time that the salivary IgM repertoire is distinct in Id3−/− mice and IgM
reactivity to Ro52, Ro60, and La specifically is concentrated in the B cells from salivary tissue in these
animals. Although the reasons for this observation are unclear at present, IgM+ B cells may bind
autoantigens in the periphery where they become activated. They then may migrate to salivary tissue in a
stochastic manner, where they are retained in the tissue. Alternatively, IgM+ B cells with specificity for SS
autoantigens may be preferentially recruited to glandular tissue, where they then become activated. Thus,
although it is clear that IgM+ B cells with reactivity to SS autoantigens preferentially populate salivary
tissue in our disease model, it remains to be determined whether B cells with antinuclear antigen
specificity undergo directional migration to salivary tissue or enter stochastically and are then retained at
that site. Studies in humans provide limited data to support both possibilities. One study demonstrated
clonal expansion of B cells derived from salivary tissue and lymph nodes of a patient with SS, although
most of the Ig examined was polyclonal in nature [57]. Additional work shows salivary gland
accumulation of CXCR4+, CXCR5+, CD27+ memory B cells in patients with SS [69], suggesting B cells
expressing high levels of these receptors are preferentially recruited to salivary tissue by CXCL12 and
CXCL13. However, whether these B cells have specificity for Ro and La is unknown at present.
The importance of ID3 in human SS is unclear, as a study using human minor salivary gland tissue derived
from patients with SS did not reveal any significant differences in ID3 expression or any genetic
abnormalities in ID3 itself [70]. Nonetheless, it is intriguing to speculate that TCR-mediated T cell
selection during T cell development may alter B cell characteristics and drive SS pathogenesis.
Importantly, mice that are genetically deficient in Id3 show defects in both positive and negative T cell
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable
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selection [71]. Elegant experiments by Li et al. [9] suggest that defects in thymic T cell selection are
responsible for the generation and accumulation of autoreactive T cells in Id3−/− mice because animals that
receive thymectomies at 3 d of age are protected from SS development. Many studies show autoreactive T
cells can promote loss of tolerance in B cells [72, 73], although the way in which T cells influence B cells
in the Id3−/− model is poorly understood. Of note, autoantibodies are observed only in aged Id3−/−
animals, and they correlate with exocrine histopathology [9]. These findings suggest pathogenic T cells
induce B cell autoreactivity, which is crucial for disease progression.
In summary, B cells derived from salivary tissue in SS mice share similar functional characteristics with
those derived from secondary immune sites. However, differences are seen in the repertoire of salivary B
cells, suggesting a role for salivary tissue in the progression of the B cell response in SS. Although further
studies in humans are needed to fully elucidate the role of the salivary tissue to shaping of the adaptive
immune response in disease, the current study suggests that salivary tissue contributes to the development
and selection of the B cell repertoire in SS.
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Figure 1.

Open in a separate window
B cells derived from spleen, cLN, and SMG show similar IgM secretion characteristics.
B cells were sort-purified from the indicated sites and stimulated with LPS (25 μg/ml) for 72 h before the ELISPOT assay
(A) Total IgM secretion in Id3−/− (spleen, n = 10; cLN, n = 9; SMG, n = 10) and C57BL/6 B cells (spleen, n = 9; cLN, n =
7). Data are shown as the percentage of total B cells secreting IgM. (B) Mean spot size of Id3−/− and C57BL/6 B cell data
in (A). Data from 2 independent experiments are shown.
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Figure 2.

Open in a separate window
Proliferative capacity of SMG B cells is similar or reduced as compared with B cells isolated from secondary
lymphoid organs.
B cells were sort-purified from the indicated site and stimulated with LPS (25 μg/ml) for 72 h before proliferation assay.
Cells were incubated with tritium or BrdU for 6 h or before harvesting. Results from 3 experiments are pooled and
normalized to SMG data from each experiment; Id3−/− (spleen, n = 13; cLN, n = 13; pooled SMG, n = 3) and C57BL/6 B
cells (spleen, n = 11; cLN, n = 12). (N.S., not significant; *P < 0.05, **P < 0.01, and ****P < 0.001).
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Figure 3.

Salivary B cells exhibit skewed IgM, VH, DH, and JH usage.
Single-cell PCR was carried out to amplify IgM sequences. (A) VH, (B) JH, and (C) DH usage analysis was performed
using IMGT on sequences from Id3−/− SMG (n = 63), cLN (n = 59), and spleen (n = 265). VH, DH, and JH numbers
correspond to the gene usage subgroup. Skewing was determined by χ2 test (*P < 0.05, **P < 0.01).
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Figure 4.

Open in a separate window

IgM derived from salivary Id3−/− B cells demonstrates short heavy-chain CDR3 lengths but similar charge and
hydrophobicity as in cLN and spleen.

Single-cell PCR was performed to amplify and sequence the IgM antibodies. (A) Total CDR-H3 amino acid length, (B)
CDR-H3 charge, and (C) CDR-H3 hydrophobicity were analyzed using sequences from Id3−/− SMG (n = 63), cLN (n =
59), and spleen (n = 265). Significance was determined with the Mann-Whitney test (*P < 0.05).
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Figure 5.

Open in a separate window
IgM derived from salivary B cells has similar mutational frequency but fewer N region additions compared with
cLN and spleen.
Single-cell PCR was performed to amplify and sequence IgM heavy-chain variable regions. (A) The number of sequences
with 1 or more mutations was determined for the variable regions. (B) The number of N region additions at the V–D and
D–J junction from Id3−/− SMG (n = 63), cLN (n = 59), and spleen (n = 265) was determined. The percentages of the
sequences with no N region additions, ≥1 at the V–D junction, ≥1 at the D–J junction, and ≥1 N additions at both
junctions are shown. Significance was determined with the χ2 test. (0, no N region additions; ≥1, ≥1 N additions; **P <
0.01, ***P < 0.001, ****P < 0.0001).

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4718196/?report=printable

21/23

10/18/2018

Analysis of IgM antibody production and repertoire in a mouse model of Sjögren’s syndrome

Figure 6.

CDR-3H amino acid usage is similar in IgM derived from spleen, cLN, and salivary B cells.
Single-cell PCR was performed to amplify and sequence IgM heavy-chain variable regions, and the CDR-H3 amino acid
usage from IgM derived from Id3−/− spleen (n = 265), cLN (n = 59), and SMG (n = 63) B cells was determined.
Differences in usage were determined with the χ2 test. (*P < 0.05).
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Figure 7.

Salivary IgM from Id3−/− B cells is enriched for Ro and La reactivity.

Open in a separate window

B cells were sort-purified from Id3−/− spleen (n = 6), cLN (n = 6), and SMG (2 separate pooled samples, n = 9 and n = 10)
and stimulated with LPS (25 μg/ml) for 6 d. Supernatant and sera were harvested for autoantigen array. Heat maps of the
log10, normalized autoantigen assay values and rank-sum analysis for each run are shown. The observed log10 assay
values are color-coded per the legend immediately to the right of the figure. The assay heat maps are color-coded across
the entire set of assays depicted for each run, and the rank-sum analysis heat maps are color-coded across each row for
each run. Sample type and run are indicated.
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